Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia ; volume:37 ; number:12 ; day:25 ; month:10 ; year:2023 ; pages:2346-2355 ; date:12.2023
Leukemia ; 37, Heft 12 (25.10.2023), 2346-2355, 12.2023
- Urheber
-
v. Stackelberg, Arend
Jäschke, Katja
Jousseaume, Etienne
Templin, Corinna
Jeratsch, Ulli
Kosmides, Daniela
Steffen, Ingo
Gökbuget, Nicola
Peters, Christina
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41375-023-02042-4
- URN
-
urn:nbn:de:101:1-2024021413121480286215
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:22 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- v. Stackelberg, Arend
- Jäschke, Katja
- Jousseaume, Etienne
- Templin, Corinna
- Jeratsch, Ulli
- Kosmides, Daniela
- Steffen, Ingo
- Gökbuget, Nicola
- Peters, Christina
- SpringerLink (Online service)
Ähnliche Objekte (12)
Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059
Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia
DNA methylation holds prognostic information in relapsed precursor B-cell acute lymphoblastic leukemia
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States
Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia
Integrated analysis of relapsed B-cell precursor Acute Lymphoblastic Leukemia identifies subtype-specific cytokine and metabolic signatures
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab
Genetic alterations in childhood relapsed high hyperdiploid B-cell acute lymphoblastic leukemia
Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059
Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia
DNA methylation holds prognostic information in relapsed precursor B-cell acute lymphoblastic leukemia
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States
Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia
Integrated analysis of relapsed B-cell precursor Acute Lymphoblastic Leukemia identifies subtype-specific cytokine and metabolic signatures
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab
Genetic alterations in childhood relapsed high hyperdiploid B-cell acute lymphoblastic leukemia
Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059
Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia
DNA methylation holds prognostic information in relapsed precursor B-cell acute lymphoblastic leukemia
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States
Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia
Integrated analysis of relapsed B-cell precursor Acute Lymphoblastic Leukemia identifies subtype-specific cytokine and metabolic signatures
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab